|
KMID : 0927720070080010074
|
|
Korean Clinical Diabetes
2007 Volume.8 No. 1 p.74 ~ p.80
|
|
|
The Effect of Mosapride, 5HT-4 Agonist on Insulin Sensitivity of Patients with IGT and High Risk Group of Type 2 Diabetes Mellitus
|
|
Nam Joo-Young
Song Young-Duk
Cho Min-Ho
Jung Han-Young
Yoon Ji-Eun
Nam Ji-Sun
Kim Hai-Jin
Park Jong-Suk
Kang Eun-Seok
Ahn Chul-Woo
Cha Bong-Soo
Lim Sung-Kil
Kim Kyung-Rae
Lee Hyun-Chul
|
|
|
Abstract
|
|
|
Introduction: Mosapride, a benzamide derivative, is widely used in patients with motility disorders as a prokinetic agent. Recent studies suggested that mosapride may modulate the secretion and/or action of insulin through 5HT receptors. So we investigated the potential effect of mosapride on insulin sensitivity in subjects with impaired glucose tolerance, having high risks for Type 2 diabetes mellitus.
Methods: Thirty subjects were selected for this study with informed consent (20: mosapride group, 10: placebo control group). Insulin sensitivity was measured by euglycemic Hyperinsulinemic clamp, before and after two weeks of mosapride administration.
Results: No difference was found between the two groups in terms of sex, age, BMI, blood pressure, total cholesterol, triglyceride and HDL-cholesterol. After 2 weeks treatment of mosapride, fasting plasma glucose levels and insulin levels were decreased. Follow-up glucose disposal rates were higher than the Initial values, and were comparable to those of control subjects.
Conclusion: Mosapride improved insulin action in pre-diabetic subjects and it can be regarded as a supplementary insulin sensitizer.
|
|
|
KEYWORD
|
|
|
Euglycemic hyperinsulinemic clamp, Insulin resistance, Mosapride
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|